| Literature DB >> 33036910 |
Marcelo Hill1, Mercedes Segovia2, Sofía Russo2, Maria Romina Girotti3, Gabriel A Rabinovich4.
Abstract
Recent studies have reported paradoxical roles of inflammation in tumor immunity triggered by PD-1 checkpoint antibody (Ab) blockade. Here, we elaborate on this controversy and propose a new perspective that might help understand this paradox. Since inflammatory cytokines and PD-1 blockade are known to target different subsets of exhausted CD8+ T cells, we propose that the timing at which anti-PD-1 Ab therapy and cytokine modulation occur might determine the fate of exhausted CD8+ T cells and perhaps, the clinical outcome of immunotherapeutic modalities.Entities:
Mesh:
Substances:
Year: 2020 PMID: 33036910 DOI: 10.1016/j.it.2020.09.003
Source DB: PubMed Journal: Trends Immunol ISSN: 1471-4906 Impact factor: 16.687